Sunvozertinib is a prescription medication used to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has a specific genetic anomaly called an epidermal growth factor receptor (EGFR) exon 20 insertion mutation. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Zegfrovy (TN). Its PubChem CID is 139377809.
Sunvozertinib
| CAS No | 2370013-12-8 |
|---|---|
| Molecular Formula | C29H35ClFN7O3 |
| Molecular Weight | 584.1 g/mol |
| Synonyms | N-[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Sunvozertinib is a prescription medication used to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has a specific genetic anomaly called an epidermal growth factor receptor (EGFR) exon 20 insertion mutation.
The listed CAS number is 2370013-12-8.
The listed molecular formula is C29H35ClFN7O3.
The listed molecular weight is 584.1 g/mol.
N-[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide.
The source lists Zegfrovy (TN).